NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Trialjectory ("the Company"), an AI-powered decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials, announced today it is currently working with more than 50 pharmaceutical companies, emerging biotechs and Contract Research Organizations to develop and execute clinical trials that focus more on patients' unique medical and personal needs – an increase of 800 percent since the beginning of 2020.
- With more than 3 million treatment matches to date, Trialjectory has grown its database from 2,000 clinical trials in 2019 to over 20,000 trials in 2022.
- "The first step toward increasing all enrollment in clinical studies is to address the fears and myths about what it means to participate in a clinical trial.
- "Since partnering with Trialjectory, MPNRF has accelerated clinical trial access for patients living with myeloproliferative neoplasms (MPN).
- Working directly with patients, healthcare providers and pharmaceutical companies, Trialjectory democratizes access to advanced cancer treatment and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials.